A5014882423- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Immunotherapy and Immune Responses
- Food Security and Health in Diverse Populations
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Bacterial Infections and Vaccines
- Multiple Myeloma Research and Treatments
- Census and Population Estimation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Monoclonal and Polyclonal Antibodies Research
University of Birmingham
2022-2023
Office for National Statistics
2010
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity efficacy of SARS-CoV-2 vaccines patients with antibody deficiency is poorly understood.
The importance of salivary SARS-CoV-2 antibodies, following infection and vaccination, has not been fully established. 875 healthcare workers were sampled during the first wave in 2020 66 longitudinally response to Pfizer BioNTech 162b2 vaccination. We measured total IgGAM individual IgG, IgA IgM antibodies. seroprevalence was 39.9%; however, only 34.1% seropositive individuals also had Infection generated serum IgG antibodies 51.4% individuals. In contrast, antibody responses dominated by...
We report the case of a 38‐year‐old man who developed IgA myeloma donor origin 7 years after allogeneic renal transplant. The diagnosis multiple was unequivocal and based on positive results from serum electrophoresis, skeletal survey bone marrow investigations. cells confirmed by DNA fingerprinting. believe this is first reported disseminated developing transplant and, as such, gives some insight into natural history biology disease.
Abstract Variants of SARS-CoV-2 may evade natural and vaccine induced immunity monoclonal antibody immunotherapeutics. There is an urgent need to know how well antibodies, by healthy Clinically Extremely Vulnerable (CEV) patients, will bind thus help reduce transmission severity infection from variants concern (VOC). This study determines the cross-reactive binding serum antibodies obtained prior 28 days after a third vaccination in three cohorts; health care worker cohort who received doses...